At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CDIO CARDIO DIAGNOSTICS HOLDINGS INC
Market Closed 11-22 16:00:00 EST
0.2654
+0.0180
+7.28%
盘后0.2659
+0.0005+0.19%
19:58 EST
High0.2695Low0.2400Vol543.99K
Open0.2400D1 Closing0.2474Amplitude11.92%
Mkt Cap10.73MTradable Cap5.29MTotal Shares40.44M
T/O140.64KT/O Rate2.73%Tradable Shares19.92M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--
Cardio Diagnostics Holdings Third Quarter 2024 Earnings: Misses Expectations
Simply Wall St.  ·  11-16
Cardio Diagnostics Holdings Third Quarter 2024 Earnings: Misses Expectations
Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference
Business Wire  ·  11-12
Cardio Diagnostics Holdings, Inc. to Sponsor and Showcase AI-Powered Solutions at the FLAACOs Annual Conference
Cardio Diagnostics Holdings Inc: CMS Issued Preliminarily Determination to Price Both Precisionchd and EPI+Gen Chd on a ‘Gapfill’ Basis
THOMSON REUTERS  ·  10-01
Cardio Diagnostics Holdings Inc: CMS Issued Preliminarily Determination to Price Both Precisionchd and EPI+Gen Chd on a ‘Gapfill’ Basis
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
Business Wire  ·  10-01
Cardio Diagnostics Holdings, Inc. Receives Preliminary Medicare Pricing from Centers for Medicare and Medicaid Services (CMS) for AI-Powered Cardiovascular Tests
Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics' Heart Disease Tests
ACCESSWIRE  ·  09-18
Potential Catalyst Right Around The Corner? CMS To Announce Preliminary Medicare Payment For Cardio Diagnostics' Heart Disease Tests
Cardio Diagnostics Price Target Maintained With a $2.00/Share by Benchmark
Dow Jones  ·  08-27
Cardio Diagnostics Price Target Maintained With a $2.00/Share by Benchmark
Cardio Diagnostics Holdings Inc expected to post a loss of 11 cents a share - Earnings Preview
Reuters  ·  08-10
Cardio Diagnostics Holdings Inc expected to post a loss of 11 cents a share - Earnings Preview
Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions
Business Wire  ·  07-29
Cardio Diagnostics Holdings Inc. Launches CDIO.AI, A Redesigned Website Enhancing User Experience and Highlighting Our AI-Driven Cardiovascular Solutions
Cardio Diagnostics' Heart Attack Risk Assessment Test Available at Meijer Supercenter in Illinois; Shares Rise
MT Newswires Live  ·  06-27
Cardio Diagnostics' Heart Attack Risk Assessment Test Available at Meijer Supercenter in Illinois; Shares Rise
Cardio Diagnostics' Heart Attack Risk Assessment Test Available at Meijer Supercenter in Illinois; Shares Rise
MT Newswires Live  ·  06-27
Cardio Diagnostics' Heart Attack Risk Assessment Test Available at Meijer Supercenter in Illinois; Shares Rise
Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois
Business Wire  ·  06-27
Cardio Diagnostics Announces Its Epi+Gen CHD Heart Attack Risk Assessment Test is Now Available at Meijer Supercenter in McHenry, Illinois
Cardio Diagnostics Announces It’s Exhibiting at the 2024 Onsite Employee Health Clinics Forum
Business Wire  ·  06-25
Cardio Diagnostics Announces It’s Exhibiting at the 2024 Onsite Employee Health Clinics Forum
Cardio Diagnostics Holdings, Inc. Achieves Soc 2 Type I Compliance Certification for Security and Confidentiality
THOMSON REUTERS  ·  06-10
Cardio Diagnostics Holdings, Inc. Achieves Soc 2 Type I Compliance Certification for Security and Confidentiality
Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality
Business Wire  ·  06-10
Cardio Diagnostics Holdings, Inc. Achieves SOC 2 Type I Compliance Certification for Security and Confidentiality
Cardio Diagnostics Holdings Inc -on June 3, Got Notice From Nasdaq, Company Is No Longer in Compliance With Nasdaq Listing Rule 5550(a)(2)
THOMSON REUTERS  ·  06-08
Cardio Diagnostics Holdings Inc -on June 3, Got Notice From Nasdaq, Company Is No Longer in Compliance With Nasdaq Listing Rule 5550(a)(2)
Benchmark Raises Price Target on Cardio Diagnostics to $2 From $1.35, Maintains Speculative Buy Rating
MT Newswires Live  ·  06-06
Benchmark Raises Price Target on Cardio Diagnostics to $2 From $1.35, Maintains Speculative Buy Rating
Benchmark Raises Price Target on Cardio Diagnostics to $2 From $1.35, Maintains Speculative Buy Rating
MT Newswires Live  ·  06-06
Benchmark Raises Price Target on Cardio Diagnostics to $2 From $1.35, Maintains Speculative Buy Rating
Cardio Diagnostics Is Maintained at Speculative Buy by Benchmark
Dow Jones  ·  06-06
Cardio Diagnostics Is Maintained at Speculative Buy by Benchmark

Introduction

Company Name.
CARDIO DIAGNOSTICS HOLDINGS INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Issue price:
--